DC Field | Value | Language |
---|---|---|
dc.contributor.author | Laborda, Eduardo | ko |
dc.contributor.author | Mazagova, Magdalena | ko |
dc.contributor.author | Shao, Sida | ko |
dc.contributor.author | Wang, Xinxin | ko |
dc.contributor.author | Quirino, Herlinda | ko |
dc.contributor.author | Woods, Ashley K. | ko |
dc.contributor.author | Hampton, Eric N. | ko |
dc.contributor.author | Rodgers, David T. | ko |
dc.contributor.author | Kim, Chan Hyuk | ko |
dc.contributor.author | Schultz, Peter G. | ko |
dc.contributor.author | Young, Travis S. | ko |
dc.date.accessioned | 2018-01-22T09:03:04Z | - |
dc.date.available | 2018-01-22T09:03:04Z | - |
dc.date.created | 2017-11-14 | - |
dc.date.created | 2017-11-14 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.18, no.11, pp.2259 - 2266 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.uri | http://hdl.handle.net/10203/237715 | - |
dc.description.abstract | The treatment of patients with acute myeloid leukemia (AML) with targeted immunotherapy is challenged by the heterogeneity of the disease and a lack of tumor-exclusive antigens. Conventional immunotherapy targets for AML such as CD33 and CD123 have been proposed as targets for chimeric antigen receptor (CAR)-engineered T-cells (CAR-T-cells), a therapy that has been highly successful in the treatment of B-cell leukemia and lymphoma. However, CD33 and CD123 are present on hematopoietic stem cells, and targeting with CAR-T-cells has the potential to elicit long-term myelosuppression. C-type lectin-like molecule-1 (CLL1 or CLEC12A) is a myeloid lineage antigen that is expressed by malignant cells in more than 90% of AML patients. CLL1 is not expressed by healthy Hematopoietic Stem Cells (HSCs), and is therefore a promising target for CAR-T-cell therapy. Here, we describe the development and optimization of an anti-CLL1 CAR-T-cell with potent activity on both AML cell lines and primary patient-derived AML blasts in vitro while sparing healthy HSCs. Furthermore, in a disseminated mouse xenograft model using the CLL1-positive HL60 cell line, these CAR-T-cells completely eradicated tumor, thus supporting CLL1 as a promising target for CAR-T-cells to treat AML while limiting myelosuppressive toxicity. | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.title | Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia | - |
dc.type | Article | - |
dc.identifier.wosid | 000416811300033 | - |
dc.identifier.scopusid | 2-s2.0-85032588778 | - |
dc.type.rims | ART | - |
dc.citation.volume | 18 | - |
dc.citation.issue | 11 | - |
dc.citation.beginningpage | 2259 | - |
dc.citation.endingpage | 2266 | - |
dc.citation.publicationname | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.identifier.doi | 10.3390/ijms18112259 | - |
dc.contributor.localauthor | Kim, Chan Hyuk | - |
dc.contributor.nonIdAuthor | Laborda, Eduardo | - |
dc.contributor.nonIdAuthor | Mazagova, Magdalena | - |
dc.contributor.nonIdAuthor | Shao, Sida | - |
dc.contributor.nonIdAuthor | Wang, Xinxin | - |
dc.contributor.nonIdAuthor | Quirino, Herlinda | - |
dc.contributor.nonIdAuthor | Woods, Ashley K. | - |
dc.contributor.nonIdAuthor | Hampton, Eric N. | - |
dc.contributor.nonIdAuthor | Rodgers, David T. | - |
dc.contributor.nonIdAuthor | Schultz, Peter G. | - |
dc.contributor.nonIdAuthor | Young, Travis S. | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.